Athena Bioscience’s Qdolo (tramadol hydrochloride) Receives US FDA’s NDA Approval for Oral Solution

 Athena Bioscience’s Qdolo (tramadol hydrochloride) Receives US FDA’s NDA Approval for Oral Solution

Athena Bioscience’s QDOLO (tramadol hydrochloride) Receives US FDA’s NDA Approval for Oral Solution

Shots:

  • Athena Biosciences announced that the US FDA has approved Qdolo (tramadol hydrochloride) oral solution 5mg/1mL C-IV
  • The most common AE’s (≥15.0%) observed in patients were dizziness/vertigo, nausea, constipation, headache, somnolence, vomiting, and pruritus
  • Qdolo is indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It will be available at chain, independent, and specialty pharmacies

    Click here to­ read the full press release/ article | Ref: PRNewswire  | Image: Pharma Compass

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post